publication venue for
- Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals.. 42:666-719. 2025
- Correction to: PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly. 41:2531-2533. 2024
- Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial. 41:2500-2518. 2024
- “You Take This Day by Day, Come What May”: A Qualitative Study of the Psychosocial Impacts of Living with Duchenne Muscular Dystrophy. 41:2460-2476. 2024
- Exploring Perceptions of Biologic Therapies: A Qualitative Study Among Canadians Living with Severe Asthma. 41:1401-1418. 2024
- Health Economic Assessments of Hyaluronic Acid Treatments for Knee Osteoarthritis: A Systematic Review. 41:65-81. 2024
- Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics. 40:5536-5546. 2023
- Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease. 40:4421-4439. 2023
- PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly. 40:671-690. 2023
- The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD. 39:3881-3895. 2022
- Clinical Radiofrequency Ablation Outcomes of Combined Sensory Nerve Branch and Dorsal Entry Root Zone Complex Lesions for Sacroiliac Joint Complex Pain. 39:3539-3546. 2022
- Recommendations from a Working Group on Obesity Care Competencies for Healthcare Education in the UK: A Report by the Steering Committee.. 39:3019-3030. 2022
- Economic Evaluation of Budesonide Orodispersible Tablets for the Treatment of Eosinophilic Esophagitis: A Cost–Utility Analysis. 38:5737-5751. 2021
- Psychometric Evaluation of ITP Life Quality Index (ILQI) in a Global Survey of Patients with Immune Thrombocytopenia. 38:5791-5808. 2021
- Efficacy of Agomelatine 25–50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies. 38:1567-1583. 2021
- Global Quality Statements on Reliever Use in Asthma in Adults and Children Older than 5 Years of Age. 38:1382-1396. 2021
- Naltrexone’s Impact on Cancer Progression and Mortality: A Systematic Review of Studies in Humans, Animal Models, and Cell Cultures. 38:904-924. 2021
- The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease. 36:3279-3287. 2019
- The Impact of Excluding Patients with End-Stage Knee Disease in Intra-Articular Hyaluronic Acid Trials: A Systematic Review and Meta-Analysis. 36:147-161. 2019
- A Comparison Between Rheological Properties of Intra-articular Hyaluronic Acid Preparations and Reported Human Synovial Fluid. 35:523-530. 2018
- Obesity and Mental Illness: Implications for Cognitive Functioning. 30:577-588. 2013
- Blood pressure control rates with an antihypertensive regimen including trandolapril in a canadian usual-care setting. 28:789-798. 2011
- Jet lag, circadian rhythm sleep disturbances, and depression: the role of melatonin and its analogs. 27:796-813. 2010
- Erratum to: New pharmacotherapy for stroke prevention in atrial fibrillation. 27:493-493. 2010
- New pharmacotherapy for stroke prevention in atrial fibrillation: Update 2010. 26:1058-1071. 2009
- Ramelteon: a review of its therapeutic potential in sleep disorders. 26:613-626. 2009
- The dilution of benzalkonium chloride (BAK) in the tear Film. 23:835-841. 2006
- Twice-daily and once-daily nedocromil sodium 2% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. 19:9-16. 2002
- Nedocromil sodium in golfers with seasonal allergic conjunctivitis. 18:195-204. 2001
- Efficacy and acceptability of nedocromil sodium 2% and olopatadine hydrochloride 0.1% in perennial allergic conjunctivitis. 17:140-147. 2000